

## Results of Annual General Meeting

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") today held an Annual General Meeting of Members at DoubleTree by Hilton Perth Waterfront, 1 Barrack Square, Perth.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure which accompanies this release.

### Authority

This announcement has been authorised for release by the Company Secretary of Neurotech International Limited.

### Further Information

Brian Leedman

Chairman

[b.leedman@neurotechinternational.com](mailto:b.leedman@neurotechinternational.com)

+61 (0)41 228 1780

Winton Willesee

Non-Executive Director

[winton@azc.com.au](mailto:winton@azc.com.au)

+61 (0)41 066 7844

### Media:

Juliana Roadley

IR Department

[juliana.roadley@irdepartment.com.au](mailto:juliana.roadley@irdepartment.com.au)

+61 (0)41 488 9863

### About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>

# Disclosure of Poll Votes

## NEUROTECH INTERNATIONAL LIMITED

Annual General Meeting

Thursday, 18 November 2021



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Approval of Remuneration Report	P	77,542,484	76,625,554 98.82%	760,930 0.98%	22,693,572	156,000 0.20%	83,831,554 99.10%	760,930 0.90%	22,693,572
2 Election of Ms Krista Bates as a Director	P	115,614,236	92,432,734 79.95%	83,756 0.07%	0	23,097,746 19.98%	123,030,480 99.93%	83,756 0.07%	0
3 Election of Professor Allan Cripps AO as a Director	P	115,614,236	92,500,908 80.01%	83,756 0.07%	0	23,029,572 19.92%	123,030,480 99.93%	83,756 0.07%	0
4 Re-election of Mr Mark Davies as a Director	P	115,614,236	92,501,734 80.01%	14,756 0.01%	0	23,097,746 19.98%	123,099,480 99.99%	14,756 0.01%	0
5 Additional capacity to issue Equity Securities	P	115,102,655	91,673,701 79.65%	399,382 0.35%	511,581	23,029,572 20.01%	122,203,273 99.67%	399,382 0.33%	511,581
6 Fees to non-executive Directors	P	77,210,903	75,930,421 98.34%	944,482 1.22%	28,337,589	336,000 0.44%	83,586,421 98.88%	944,482 1.12%	28,337,589
7 Issue of Options to Ms Krista Bates	P	77,722,484	77,133,810 99.24%	245,174 0.32%	0	343,500 0.44%	84,347,310 99.71%	245,174 0.29%	450,000



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Issue of Options to Professor Allan Cripps AO	P	77,722,484	77,137,810 99.25%	173,000 0.22%	0	411,674 0.53%	84,419,484 99.80%	173,000 0.20%	0

